Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Bitcoin USD

    70,764.52
    +649.82 (+0.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.61
    +24.63 (+0.31%)
     
  • Gold

    2,232.00
    +19.30 (+0.87%)
     
  • Crude Oil

    82.42
    +1.07 (+1.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Sanofi says M&A strategy to remain disciplined

A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo

(Reuters) - French drugmaker Sanofi (SASY.PA) will remain disciplined in its pursuit of takeover targets and potential therapeutic areas include oncology, immunology, multiple sclerosis and rare diseases, its finance chief and CEO said on Friday.

When asked whether Sanofi would continue to focus on deal targets in oncology after it was beaten out in the pursuit of U.S. cancer drug company Medivation (MDVN.O), Chief Executive (CEO) Olivier Brandicourt said, while cancer deals were still possible, internal drug development and collaboration with external partners might be enough to reach growth targets.

"We are opening our M&A strategy, as we said last year, to segments where have a good presence but where we need to strengthen our presence with inorganic growth, we mentioned immunology and we mentioned MS... rare disease can also be an area," Brandicourt told analyst in a conference call.

(Reporting by Ludwig Burger; editing by Edward Taylor)